[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:primary-cutaneous-diffuse-large-b-cell-lymphoma-leg-type":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":16,"states":17},"Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type",1,0,[8],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05821088","Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed\u002F Refractory Large B-Cell Lymphoma",[12],"Phase 2","ACTIVE_NOT_RECRUITING","2026-08-03T03:19:35.241322Z","2026-05-05T02:43:26.683044Z",[],[]]